stockrowRoivant Sciences Ltd.
ROIV Healthcare Biotechnology
Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.
- Revenue
- −33.6%
- EPS
- +21.2%
- Free cash flow
- −30.0%
Quarter to June 2026, against a year earlier
Follow ROIV
Alert me
Roivant Sciences Ltd. (ROIV) Revenue growth
Roivant Sciences Ltd.'s revenue growth over the twelve months to 30 June 2026 was −67.6%, up 4.0 percentage points from fiscal 2026 (−71.6%). Over the past ten years it has ranged from −71.6% (fiscal 2026) to 132.3% (fiscal 2022) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 6.26% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2026 | −71.6% | (60.38) |
| FY2025 | −11.2% | 35.43 |
| FY2024 | −46.6% | (57.46) |
| FY2023 | 10.8% | (121.50) |
| FY2022 | 132.3% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | −33.6% | 33.16 |
| Mar 2026 | −66.7% | 11.12 |
| Dec 2025 | −77.8% | (12.94) |
| Sep 2025 | −64.9% | 7.95 |
| 17 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| RVMD Revolution Medicines, Inc. compare | 491.1% |
| INSM Insmed, Inc. compare | 240.0% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 56.2% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 32.9% |
| INCY Incyte Corporation compare | 24.9% |
| GMAB Genmab A/S Sponsored ADR compare | 22.3% |
| RPRX Royalty Pharma PLC compare | 11.4% |
| BNTX BioNTech SE Sponsored ADR compare | −22.7% |
| ROIV Roivant Sciences Ltd. | −67.6% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on ROIV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- The full statement